With another GH/IGF-axis medicine
Safety flag
Duplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.
Interaction evidence source All research profiles
Blends
AOD-9604 / CJC-1295 / Ipamorelin
Prepared by the ezGLP team. Sources last checked . Profile reviewed .
Also known as AOD-9604 + CJC-1295 + Ipamorelin
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Educational overview
AOD-9604 / CJC-1295 / Ipamorelin is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
This is a compounded or grey-market blend that combines three unrelated peptides in one vial. AOD-9604 is a synthetic fragment of the C-terminal end of human growth hormone that was developed as an anti-obesity agent and does not stimulate growth hormone release. CJC-1295 is a long-acting analogue of growth-hormone-releasing hormone, and ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor. Vendors market the mixture for fat loss and body composition on the reasoning that two secretagogues raise growth hormone while the fragment adds a lipolytic effect. No pharmaceutical company developed the combination, and the ratios sold differ between suppliers.
No clinical trial has studied this three-peptide combination, so evidence exists only for the components separately and cannot be added together. CJC-1295 raised growth hormone two- to ten-fold and IGF-1 for more than a week in two small placebo-controlled studies in healthy adults published by its developer in 2006, with an estimated half-life of about six to eight days. Ipamorelin was characterised in animals in 1998 and later failed to beat placebo in a 114-patient phase 2 trial for postoperative ileus. AOD-9604 reduced weight gain in obese rodents but its human obesity programme was discontinued after a phase 2b trial did not show meaningful weight loss. None of the three has completed development.
None of the components is approved by the FDA, the EMA or any other regulator, and the blend itself is an unapproved compounded product. The FDA's table of bulk substances that may present significant safety risks lists all three: AOD-9604 (nominated for compounding, then withdrawn) for limited safety data and possible serious adverse events, CJC-1295 for serious adverse events including increased heart rate and a systemic vasodilatory reaction, and ipamorelin acetate, placed in category 2 under the 503B interim policy in September 2023, for immunogenicity concerns and a published study that reported serious adverse events including death when the peptide was given intravenously. Growth hormone releasing factors and fragments are prohibited at all times by the World Anti-Doping Agency.
There is no product label for the combination, and the components differ in stability, so no authoritative storage or beyond-use guidance exists. Suppliers usually ship a lyophilised powder with a request to keep it cold and away from light, and a reconstituted multi-peptide solution has no established in-use period. Because a single vial contains three actives at a vendor-chosen ratio, an inventory record that captures the labelled amount of each component, the supplier, batch identifier, reconstitution date and resulting concentration is what allows a later dose log entry to be interpreted at all. Entries that record only a volume cannot be reconciled against any of the component literature.
- Category
- Blends
- Routes represented
- Subcutaneous (SubQ)
- Storage context
- Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.
Published literature
Safety evidence
Serious or important: peptide immunogenicity, aggregation, or impurity concerns.
Route-specific human safety and long-term adverse effects are not established.
Safety evidence sourceInteraction evidence
These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
Common questions
Is the AOD-9604, CJC-1295 and ipamorelin blend FDA approved?
No. None of the three peptides is an approved drug anywhere, and the mixture has never been submitted to a regulator. The FDA lists AOD-9604, CJC-1295 and ipamorelin acetate among bulk substances that may present significant safety risks in compounding, citing immunogenicity, peptide impurities, limited human safety data and, for CJC-1295 and ipamorelin, specific serious adverse events. Products sold as research chemicals are unapproved drugs when marketed for human use.
Has the combination of AOD-9604, CJC-1295 and ipamorelin been studied in humans?
No published trial has tested the three together. The evidence base consists of separate studies: two small developer-run studies of CJC-1295 in healthy adults in 2006, a 2014 phase 2 trial of intravenous ipamorelin for postoperative ileus that did not beat placebo, and an AOD-9604 obesity programme abandoned after phase 2b. Whether the components interact, add or interfere with one another pharmacologically has not been examined.
What does each peptide in the blend do?
CJC-1295 mimics growth-hormone-releasing hormone and, in a developer study, increased growth hormone and IGF-1 for days after a single injection because of its long half-life. Ipamorelin activates the ghrelin receptor to trigger growth hormone pulses with comparatively little effect on cortisol or prolactin in animal work. AOD-9604 copies a fragment of growth hormone itself and was intended to promote fat breakdown without raising IGF-1; human trials did not confirm weight loss.
What are the risks of a CJC-1295 and ipamorelin blend with AOD-9604?
The FDA has identified increased heart rate and a systemic vasodilatory reaction with CJC-1295, serious adverse events including death in a study of intravenous ipamorelin, and adverse events of unclear causality with AOD-9604. Beyond those, the agency flags immunogenicity for certain routes, peptide-related impurities and difficulty characterising the active ingredients. Long-term effects of sustained growth hormone and IGF-1 elevation from secretagogues are not established, and the combination itself has no safety data.
Further reading
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
- FDA briefing document, Pharmacy Compounding Advisory Committee, December 4, 2024 (AOD-9604)
- Teichman et al., J Clin Endocrinol Metab 2006 (CJC-1295 in healthy adults)
- Raun et al., Eur J Endocrinol 1998 (ipamorelin, the first selective GH secretagogue)
- Beck et al., Int J Colorectal Dis 2014 (ipamorelin phase 2 trial in postoperative ileus)
- Ng et al., Horm Res 2000 (metabolic studies of AOD9604 in obese Zucker rats)
- World Anti-Doping Agency, The Prohibited List
Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live. Consult a licensed healthcare professional.